Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT00328562
Official study title

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Study summary

The purpose of this study is to determine the safety and effectiveness of Iressa when used with a short course of high dose radiation therapy in patients with lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedZD1839 (Iressa) and Thoracic Radiotherapy

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 4, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Interventions being studied
Drug: ZD1839 (Iressa); Radiation: Thoracic Radiotherapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically confirmed non small cell lung cancer
  • Stage IV needing radiation therapy to control symptoms
  • Patients with brain metastases
  • Unresectable or medically inoperable
Reasons someone may not be able to joinExclusion criteria
  • Small cell lung cancer
  • Previous thoracic radiation therapy
  • Oxygen-dependent patients
  • Forced expiratory volume in 1 second (FEV1) less than 1.5
  • Patients with active interstitial lung disease
  • Patients with underlying lung disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Thomas Jefferson University HospitalPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 4, 2025. Always confirm current availability with the study team.

View original record ↗